UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its
Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ¨ No x
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ¨
No x
On November 24, 2025, CureVac N.V. (the “Company”) issued
a press release announcing the Company’s financial results for the third quarter and first nine months of 2025 and provided a business
update.
The information included in this Form 6-K (including Exhibit
99.1, but excluding the statement of the Company’s Chief Executive Officer contained in Exhibit 99.1 hereto) shall be deemed to
be filed and incorporated by reference in BioNTech SE’s registration statement on Form F-4 (File No. 333-289468) and
to be part thereof from the date on which this Form 6-K is filed, to the extent not superseded by documents or reports subsequently
filed.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
CureVac N.V. |
|
|
| |
(Registrant) |
|
|
| |
|
|
|
| By: |
/s/ Axel Sven Malkomes |
|
By: |
/s/ Alexander Zehnder |
| |
Chief Financial Officer |
|
|
Chief Executive Officer |
| |
|
|
|
|
| |
Date: November 24, 2025 |
|
|
|
EXHIBIT INDEX
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1 |
|
CureVac N.V. Press Release dated November 24, 2025 |
